17805064

Source:http://linkedlifedata.com/resource/pubmed/id/17805064

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0079083, umls-concept:C0123931, umls-concept:C0282460, umls-concept:C0684249, umls-concept:C0935989, umls-concept:C1516224
pubmed:issue	9
pubmed:dateCreated	2007-9-6
pubmed:abstractText	The tyrosine kinase KIT has variable expression in small-cell lung cancer (SCLC) and may be a prognostic factor. Imatinib targets KIT expression, providing rationale for studying its role in combination with chemotherapy in SCLC in a multicenter phase II trial.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101274235
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin, http://linkedlifedata.com/resource/pubmed/chemical/Piperazines, http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines, http://linkedlifedata.com/resource/pubmed/chemical/Radiation-Sensitizing Agents, http://linkedlifedata.com/resource/pubmed/chemical/imatinib, http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1556-1380
pubmed:author	pubmed-author:BurrisHoward AHA3rd, pubmed-author:GrapskiRichardR, pubmed-author:GrecoF AnthonyFA, pubmed-author:HainsworthJohn DJD, pubmed-author:MallidiPadmaja VPV, pubmed-author:MengChristinaC, pubmed-author:Minnie Pearl Cancer Research Network, pubmed-author:SchreederMarshallM, pubmed-author:SimonsLisaL, pubmed-author:SpigelDavid RDR, pubmed-author:YardleyDenise ADA
pubmed:issnType	Electronic
pubmed:volume	2
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	854-61
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:17805064-Administration, Oral, pubmed-meshheading:17805064-Adult, pubmed-meshheading:17805064-Aged, pubmed-meshheading:17805064-Aged, 80 and over, pubmed-meshheading:17805064-Antineoplastic Agents, pubmed-meshheading:17805064-Camptothecin, pubmed-meshheading:17805064-Carboplatin, pubmed-meshheading:17805064-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:17805064-Disease Progression, pubmed-meshheading:17805064-Drug Administration Schedule, pubmed-meshheading:17805064-Female, pubmed-meshheading:17805064-Follow-Up Studies, pubmed-meshheading:17805064-Humans, pubmed-meshheading:17805064-Infusions, Intravenous, pubmed-meshheading:17805064-Lung Neoplasms, pubmed-meshheading:17805064-Magnetic Resonance Imaging, pubmed-meshheading:17805064-Male, pubmed-meshheading:17805064-Middle Aged, pubmed-meshheading:17805064-Neoplasm Staging, pubmed-meshheading:17805064-Piperazines, pubmed-meshheading:17805064-Protein-Tyrosine Kinases, pubmed-meshheading:17805064-Pyrimidines, pubmed-meshheading:17805064-Radiation-Sensitizing Agents, pubmed-meshheading:17805064-Retrospective Studies, pubmed-meshheading:17805064-Survival Rate, pubmed-meshheading:17805064-Tomography, X-Ray Computed, pubmed-meshheading:17805064-Treatment Outcome, pubmed-meshheading:17805064-Virginia
pubmed:year	2007
pubmed:articleTitle	Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
pubmed:affiliation	Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II